Coronavirus disease (COVID-19) in patients with hematologic malignancy

Abstract

The Coronavirus disease that emerged globally in 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019, with rapid worldwide spread leading to a pandemic soon after. Three years later, although the virus now holds a diminished role in the public agenda, COVID-19 remains a real and present danger for patients with hematologic malignancy (HM). This paper provides an overview of the risks of COVID-19 in patients with HM, the effectiveness of vaccination, and management strategies in these vulnerable patients.